AzTrials
AzTrials

HealthyNCT02048345

Gastrointestinal Behavior of Posaconazol in Healthy Volunteers

A study testing Suspension Fasted State, Suspension Fed State and Solution Fasted State in people with Healthy, run by KU Leuven at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to understand the behavior of posaconazol gives as a suspension and solution in the gastrointestinal tract in human volunteers. The investigators know that supersaturation for this compound can be achieved by the influence of the gastrointestinal tract: The acid environment of the stomach… Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Suspension Fasted State, Suspension Fed State and Solution Fasted State
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteBelgium
Study dates
Jan 2014to Dec 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • 18-40 years Healthy volunteers

Who cannot join

  • disease Hiv, Hepatitis B, Hepatitis C Pregnant Drug abuse

Trial locations and contacts

1 site in 1 country.

Bart Hens, Pharmacist contact

+3216330302

bart.hens@pharm.kuleuven.be

Belgium1 site, 1 recruiting
  • UZ Leuven Gasthuisberg

    Leuven, 3000

    Bart Hens, Pharmacist, +3216330302, bart.hens@pharm.kuleuven.be

    Jan Tack, PhD, MD

    Recruiting

Other trials in Belgium

About this study

The aim of this study is to understand the behavior of posaconazol gives as a suspension and solution in the gastrointestinal tract in human volunteers. The investigators know that supersaturation for this compound can be achieved by the influence of the gastrointestinal tract: The acid environment of the stomach creates a optimized environment for the basic compound to reach a high solubility, while the neutral environment of the small intestine creates a low solubility environment for the compound. The transit from stomach to small intestine gives the opportunity for the drug to create a supersaturated solution. Giving the drug as a solution to the healthy volunteer makes sure that precipitation is not occurring in the stomach and that precipitation has to happen in the small intestine. After all, supersaturation is a state that is not thermodynamic stable and always will want to precipitate. Giving the drug as a suspension to the healthy volunteers, can make it possible that still some particles of the drug are not in dissolution and that those particles will flow to the small intestine where other particles easily can bind to. This will make that almost the whole supersaturated solution is immediately precipitated.

The investigators want to give the suspension by the authorized drug called Noxafil. On the other hand an aqueous solution will be made by adjusting the pH to 1.2 (which is conform with the pH of the stomach) and given to the volunteers by the stomach catheter. This 2 formulations will be tested in a fasted state and a fed state (by giving 2 Ensure plus shakes to the volunteers before the experiment starts). After intake of the formulation, gastric and duodenal fluids will be aspirated by the catheters and analyzed at their laboratory. So the four conditions the investigators want to study are:

Read more
  1. 10 mL Suspension of posaconazol (Noxafil 40mg/mL) together with a glass of 240 mL water in a fasted state
  2. 250 mL solution of posaconazol, by dissolving 2.6 mL autohorized suspension (Noxafil) in 247 mL water, adjusted to pH 1.2 by hydrochloric acid given to the volunteer in a fasted state.
  3. 10 mL Suspension of posaconazol (Noxafil 40mg/mL) together with a glass of 240 mL water in a fed state (by giving 20 minute before intake of the formulation, 2 ensure plus shakes)
  4. 250 mL solution of posaconazol, by dissolving 2.6 mL autohorized suspension (Noxafil) in 247 mL water, adjusted to pH 1.2 by hydrochloric acid given to the volunteer in a fed state (by giving 20 minute before intake of the formulation, 2 ensure plus shakes).

By getting more knowledge about the behavior of posaconazol (interplay supersaturation / precipitation) more insights can be achieved for the development of supersaturating drug delivery systems.

Conditions
Healthy
Being tested
Suspension Fasted State, Suspension Fed State, Solution Fasted State, Solution Fed State
Keywords
ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fasted state, ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fed state, two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fasted state, two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fed state

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Suspension Fasted StateDrug

  • Suspension Fed StateDrug

  • Solution Fasted StateDrug

  • Solution Fed StateDrug

Study groups in NCT02048345
Study groupRoleWhat they receive
Suspension, fasted stateExperimentalSuspension Noxafil will be administered in the fasted state to the volunteers.
Receives: Drug: Suspension Fasted State
Suspension, with sugar (delay gastric emptying)ExperimentalSuspension will be co-administered with glucose to delay the gastric emptying time
Receives: Drug: Suspension Fed State
Solution, fasted stateExperimentalA solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
Receives: Drug: Solution Fasted State
Solution, with sugar (delaying gastric emptying)ExperimentalA solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
Receives: Drug: Solution Fed State

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concentration-time profile in stomach and small intestine for posaconazol

    Measured: These concentrations will be measured for 4 hours, together by taking blood samples to see how the drug will be transported to the blood circulation (PK profile for 48 hours)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionDec 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02048345
Sponsor's protocol ID
DDD13POSA
Status last verified
Jan 2014
First submitted
23 Jun 2013
Last updated
29 Jan 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Suspension Fasted State, Suspension Fed State and Solution Fasted State in people with Healthy, run by KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Bart Hens, Pharmacist (+3216330302, bart.hens@pharm.kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concentration-time profile in stomach and small intestine for posaconazol (time frame: These concentrations will be measured for 4 hours, together by taking blood samples to see how the drug will be transported to the blood circulation (PK profile for 48 hours)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in